GlassScriptPhysician profile
Jeffrey H Denham
NPI 1477592806
$8,327.30
in general payments reported to CMS, 2019-2025
46 companies · $870 in 2025
The $870 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,102 · 2020: $1,058 · 2021: $1,514 · 2022: $897 · 2023: $1,545 · 2024: $1,342 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,756.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,570.19 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $1,106.51 | 2019-2025 | Ubrelvy, Vraylar |
| Pfizer INC. | $623.13 | 2019-2025 | |
| Abbott Laboratories | $570.12 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $504.22 | 2019-2025 | |
| Lilly USA, LLC | $497.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $438.02 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $406.89 | 2019-2024 | Xifaxan, Trulance |
| Novo Nordisk INC | $344.63 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $176.91 | 2019-2025 | Breztri |
| Allergan, INC. | $171.11 | 2020 | |
| Amarin Pharma, INC. | $151.35 | 2019-2021 | |
| Antares Pharma, INC. | $122.01 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Almatica Pharma LLC | $110.25 | 2022-2025 | Loreev Xr |
| Corium, LLC | $99.09 | 2023 | Azstarys, Adlarity |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Denham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.